NCT01734486

Growth Response in Girls With Turner Syndrome

Growth Response in Girls With Turner Syndrome During a Three-year GH Treatment Comparing Two Dose Regimens. Identification of Predictive Factors of Growth Response

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

This trial is conducted in Europe. The aim of the trial is to evaluate growth response of two somatropin dose regimens in girls with Turner Syndrome.

Conditions

• Genetic Disorder
• Turner Syndrome

Interventions

Type	Name	Description
DRUG	somatropin	0.9 UI/kg/week. Subcutaneous injection for 3 years
DRUG	somatropin	1.8 UI/kg/week. Subcutaneous injection for 3 years

Timeline

• Start date: 1996-09-23
• Primary completion: 2003-05-21
• Completion: 2003-05-21
• First posted: 2012-11-27
• Last updated: 2017-02-28

Locations

15 sites across 1 country: France